Current Environment:

Summary

A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change).

Conditions

Autism, Autism Spectrum Disorder

Recruitment Status

Recruiting

Detailed Description

A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change). The main questions the study aims to answer are: To evaluate the stability of each potential biomarker over a 3-4-week retest period. The biomarkers are hypothesized to have adequate stability (ICC: > .5) in the absence of intervention. To determine which baseline biomarker scores predict response to a manualized cognitive behavioral therapy (CBT) program for treating anxiety, Being Brave. To determine which biomarkers are sensitive to treatment response.

Eligibility Criteria

Inclusion Criteria:

Age between 3;0 and 6;11 years old
A diagnosis of autism spectrum disorder using DSM-5 diagnostic criteria
A diagnosis of anxiety disorder using DSM-5 diagnostic criteria
Use of fluent 2-3 word phrases or fluent speech (i.e., Module 2 or 3 for ADOS-2)
Cognitive ability (either verbal or non-verbal IQ) > 80 using the DAS-2
A parent/guardian who is willing/able to participate and respond to interviews/surveys in English and willing/able to participate in Being Brave parent training in English and support homework activities.

Exclusion Criteria:

Presence of seizures
Premature birth (<36 weeks) or low birth weight (<2500 gms)
Known genetic or medical disorders (e.g., Fragile X), or injuries (e.g., stroke) with implications for the nervous system or that require regular psychoactive medication that alter EEG/RSA/EDR signal (e.g., anti-convulsants)
Significant sensory or motor impairment (e.g., blindness)
Major physical abnormalities
Exposure to environmental factors that could contribute to neurocognitive delays (significant alcohol exposure in utero, extreme environmental deprivation)
Previous CBT for anxiety
Presence of conduct or oppositional defiant disorder or ADHD so severe as to interfere with the child's ability to take part in treatment
Presence of a primary presenting problem for which the intervention would be inappropriate (e.g., obsessive-compulsive disorder, severe mood disorder, suicidality)
Psychotic symptoms in the child or parents
Parent/caregiver who is not fluent in English or English is spoken in the home less than half of the time.

Intervention

Intervention Type

Intervention Name

Behavioral

Being Brave

Phase

Not Applicable

Gender

All

Min Age

3 Years

Max Age

6 Years

Download Date

April 10, 2024

Principal Investigator

Susan Faja

This field has been modified from ClinicalTrials.gov to show a contact specific to Boston Children's.

Primary Contact Information

Susan Faja, PhD
susan.faja@childrens.harvard.edu

This field has been modified from ClinicalTrials.gov to show a contact specific to Boston Children's.

For more information on this trial, visit clinicaltrials.gov.

Contact

For more information and to contact the study team:

Biomarkers Research in Anxiety for Validation and Efficacy NCT06221176 Susan Faja, PhD susan.faja@childrens.harvard.edu